242 related articles for article (PubMed ID: 12678765)
1. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
4. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Krishna R; Mayer LD
Eur J Pharm Sci; 2000 Oct; 11(4):265-83. PubMed ID: 11033070
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships.
Di Pietro A; Dayan G; Conseil G; Steinfels E; Krell T; Trompier D; Baubichon-Cortay H; Jault J
Braz J Med Biol Res; 1999 Aug; 32(8):925-39. PubMed ID: 10454753
[TBL] [Abstract][Full Text] [Related]
8. Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.
Mayur YC; Peters GJ; Prasad VV; Lemo C; Sathish NK
Curr Cancer Drug Targets; 2009 May; 9(3):298-306. PubMed ID: 19442050
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer.
Lehne G
Curr Drug Targets; 2000 Jul; 1(1):85-99. PubMed ID: 11475537
[TBL] [Abstract][Full Text] [Related]
10. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
[TBL] [Abstract][Full Text] [Related]
11. Marine Natural Products as Models to Circumvent Multidrug Resistance.
Long S; Sousa E; Kijjoa A; Pinto MM
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399665
[TBL] [Abstract][Full Text] [Related]
12. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S; Gualtieri F
Curr Drug Targets; 2006 Jul; 7(7):893-909. PubMed ID: 16842220
[TBL] [Abstract][Full Text] [Related]
13. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators.
Safa AR
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):1-17. PubMed ID: 14754408
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
17. The role of passive transbilayer drug movement in multidrug resistance and its modulation.
Eytan GD; Regev R; Oren G; Assaraf YG
J Biol Chem; 1996 May; 271(22):12897-902. PubMed ID: 8662680
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.
Dong J; Qin Z; Zhang WD; Cheng G; Yehuda AG; Ashby CR; Chen ZS; Cheng XD; Qin JJ
Drug Resist Updat; 2020 Mar; 49():100681. PubMed ID: 32014648
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
